References
- Goldberg LH, Mamelak AJ. Review of actinic keratosis. Part 1: etiology, epidemiology and clinical presentation. J Drug Dermatol 2010;9:1125-32
- Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol. 2007;157(Suppl 2):21-4
- Quatresooz P, Piérard-Franchimont C, Paquet P, et al. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008;18:6-10
- Ulrich C. Topical treatment of field cancerization. Cancer Treat Res 2009;146:439-46
- Bianchi L, Campione E, Marulli GC, et al. Actinic keratosis treated with an immune response modifier: a case report of six patients. Clin Exp Dermatol 2003;28(Suppl 1):39-41
- Campione E, Diluvio L, Paternò EJ, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1% gel. Am J Clin Dermatol 2010;11:45-50
- Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. J Drugs Dermatol 2012;11:1462-7
- Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004;3:401-7
- Nelson CG, Spencer J, Nelson CG Jr. A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol 2007;6:712-17
- Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer. Treatment and prevention. Am J Clin Dermatol 2007;8:195-200
- Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007;156:25-33
- Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11
- Park SW, Kim HS, Choi MS, et al. The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase 2 inhibition in head and neck squamous cell carcinoma cell lines. Anticancer Drugs 2011;22:416-23
- Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996;35(Suppl 1):4-12
- Leite SR. Inhibitors of human collagenase, MMP1. Eclética Química 2009;34:87-102
- Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002;62:356-8
- Zalaudek I, Giacomei J, Argenziano G, et al. Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol 2006;155:951-6
- Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg 2000;26:728-32
- Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140:1542
- Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratoses with imiquimod 5% cream. Dermatol Surg 2005;31:659-64
- Nelson C, Rigel D. Long-term follow up of diclofenac sodium 3% in 2.5% hyaluronic acid gel for actinic keratosis: one-year evaluation. J Clin Aesthet Dermatol 2009;2:20-5
- Campione E, Paternò EJ, Candi E, et al. The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors. Drug Des Devel Ther 2015;9:5843-50
- Mirshafiey A, Vaezzadeh F, Khorramizadeh MR, Saadat F. Effect of piroxicam on matrix metalloproteinase 2 and apoptosis. Int J Tissue React 2004;26:1-7
- Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006;16:599-606
- Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709-13
- Bens G. Sunscreens. Adv Exp Med Biol 2014;810:429-63